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Abstract
Background: Cadmium has been classified as a human carcinogen, affecting health through occupational and
environmental exposure. Cadmium has a long biological half-life (>25 years), due to the flat kinetics of its
excretion. The prostate is one of the organs with highest levels of cadmium accumulation. Importantly, patients
with prostate cancer appear to have higher levels of cadmium both in the circulation and in prostatic tissues.
Results: In the current report, we demonstrate for the first time that cadmium down-regulates expression of the
X-linked inhibitor of apoptosis protein (XIAP) in prostate cancer cells. Cadmium-mediated XIAP depletion occurs at
the post-transcriptional level via an NF-B-independent, proteasome-mediated mechanism and coincides with an
increased sensitivity of prostate cancer cells to TNF-a-mediated apoptosis. Prolonged treatment with cadmium
results in selection of prostate cancer cells with apoptosis-resistant phenotype. Development of apoptosis-
resistance coincides with restoration of XIAP expression in cadmium-selected PC-3 cells.
Conclusions: Selection of cadmium-resistant cells could represent an adaptive survival mechanism that may
contribute to progression of prostatic malignancies.
Background
Cadmium is a ubiquitous environmental pollutant that
is classified as a human carcinogen by the International
Agency for Research on Cancer and the National
Toxicology Program. Exposure to cadmium and cad-
mium-containing compounds primarily occurs in the
workplace (e. g. mining, smelting, processing, product
formulations, and battery manufacturing). Meanwhile,
non-occupational exposure is also widespread and stems
from foods and tobacco smoke [1]. Furthermore, cad-
mium has been detected in significant amounts in all
tested zinc-containing dietary supplements [2]. Cad-
mium has a long biological half-life (>25 years), due to
the flat kinetics of its excretion [3]. The prostate is one
of the organs with highest levels of cadmium
accumulation [4,5]. The carcinogenic properties of cad-
mium have been extensively studied, using in vitro cell
culture and in vivo animal models. In vitro studies have
reported malignant transformation of non-tumorigenic
human prostate epithelial cells following cadmium expo-
sure. The cells transformed by cadmium demonstrate
morphological alterations, anchorage-independent
growth in soft agar, and formation of tumors when
transplanted into SCID mice [6]. In addition, cadmium
chloride has been shown to produce premalignant and/
or invasive epithelial lesions in the rat ventral prostate
when administered in drinking water [7-9]. Interestingly,
patients with prostate cancer appear to have higher
levels of cadmium both in the circulation and in pro-
static tissues [10]. Aberrant gene expression resulting in
increased cell proliferation or blockade of apoptosis may
be the mechanisms responsible for cadmium-mediated
carcinogenesis [11].
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caspase inhibitors that selectively regulate the activity of
both initiator and effector caspases [12,13]. In addition
to the regulation of apoptosis, IAPs are also involved in
various cellular functions, including cell cycle modula-
tion, intracellular signal transduction and targeting of
proteins to the ubiquitin-proteasome degradation
m a c h i n e r y[ 1 4 - 1 6 ] .O fa l lt h em e m b e r so ft h eI A P
family, the X-linked inhibitor of apoptosis protein
(XIAP) has received the most interest. XIAP is a 57 kDa
protein with three zinc-binding baculovirus IAP repeat
(BIR) domains. These domains are essential for the inhi-
bitory activity of XIAP in apoptosis. An additional zinc-
binding motif, the really interesting new gene (RING)
domain, contains E3 ubiquitin ligase activity [16].
Importantly, XIAP is the only member of the IAP family
that is able to directly inhibit both the initiation and
execution phases of the caspase cascade [17]. Many stu-
dies have revealed a strong association between XIAP
expression levels and carcinogenesis [13,17]. Elevated
XIAP protein expression is described in a number of
human cancers, including lymphoma [18], colon [19],
lung [20], renal [21], hepatocellular [22], and prostate
cells [23,24]. Increased XIAP levels have been linked to
mechanisms by which cells escape anoikis and apoptosis
that are induced by radiation, chemotherapy, and death
receptors activation [17,23,25].
Here, we demonstrate that cadmium down-regulates
the expression of XIAP at the post-transcriptional level
in prostate cancer cells. The observed modulation of
XIAP expression occurs via an NF-B-independent
mechanism and is due to cadmium-mediated inhibition
of proteasome activity.
Results
Cadmium down-regulates XIAP expression at post-
transcriptional level in prostate cancer cells
The ability of cadmium to substitute zinc in zinc finger
domains and impair function of the wild-type zinc finger
proteins has been established [26]. Given that XIAP
contains three zinc-binding BIR domains and a zinc-
binding RING domain, we examined the impact of cad-
mium on the expression of XIAP in prostate cancer cell
lines.
To establish relevance of our in vitro investigations, it
was essential to consider whether the concentrations of
cadmium used in our experiments were compatible with
those that were found in target cells of exposed organ-
isms. The concentrations of cadmium used in our study
(10-30 μM) were indeed within the range documented
for prostatic tissues in humans [27]. As demonstrated in
Figure 1A, treatment of human PC-3 and DU-145 cells
with cadmium resulted in a decrease of XIAP protein
level. Inhibition of XIAP expression is selective, as
cadmium had no effect on the levels of other members
of IAP family, namely cIAP1 and cIAP2 (Fig. 1A).
Furthermore, it is important to note that XIAP down-
regulation was observed at cadmium concentrations that
had no significant effect on cell viability (Fig 1B). To
test the possibility that cadmium modulates XIAP
expression at the transcriptional level, we examined the
levels of XIAP mRNA in PC-3 and DU-145 cells incu-
bated with cadmium by real-time PCR. As shown in
Figure 1C, XIAP mRNA levels were not suppressed by
cadmium.
Modulation of XIAP expression by cadmium occurs via
NF-B-independent, proteasome-mediated mechanism
XIAP is a protein that is regulated by NF-B [28]. Invol-
vement of the proteasome pathway in post-translational
regulation of IAPs likewise has been demonstrated
[18,29,30]. Data from our laboratory, shown in Figure
2A, demonstrate that both the NF-B inhibitor BAY 11-
7085 and the proteasome inhibitor MG132 markedly
reduce XIAP expression in PC-3 prostate cancer cells.
Importantly, reduction of XIAP expression was not sec-
ondary to a rise in cell death. The viability of cells fol-
lowing co-culture with either BAY 11-7085 or MG132
exceeded 85%, as examined by propidium iodide stain-
ing followed by flow cytometry analysis (data not
shown). Notably, expression levels of cIAP1 and cIAP2
proteins were also slightly reduced in these cells. Inhibi-
t o r ye f f e c t so fB A Y1 1 - 7 0 8 5a n dM G 1 3 2o nt h eN F - B
transcriptional activity may be responsible for this find-
ing. Recent studies document discrepant data on the
effect of cadmium on the activation of NF-B. Some
reports demonstrate cadmium-induced inhibition of NF-
B binding to DNA [31], while others note an increase
in NF-B activity in cells treated with cadmium [32,33].
Therefore, we examined the effect of cadmium on the
status of NF-B activity in PC-3 prostate cancer cells
using the luciferase reporter assay. The findings pre-
sented in Figure 2B demonstrate that NF-B activation
was markedly reduced in cells pre-treated with either
cadmium or NF-B inhibitor BAY 11-7085. Neverthe-
less, given that XIAP mRNA levels were not suppressed
in cadmium-treated cells (Fig. 1C), the results of our
experiments suggest that NF-B-controlled pathway is
n o ti n v o l v e di nc a d m i u m - m e d i a t e dd o w n - r e g u l a t i o no f
XIAP protein levels in prostate cancer cells. Importantly,
cadmium either alone (Fig. 1B) or in combination with
TNF-a (data not shown) did not affect cell viability at
the time point studied.
To examine the possibility that cadmium modulates
XIAP expression via proteasome-dependent mechan-
isms, we first examined trypsin- and chymotrypsin-like
proteasome activities in PC-3 cells cultured in the pre-
sence of cadmium. As demonstrated in Figure 2C,
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proteasome activity in PC-3 cells. Similar results were
obtained with a proteasome inhibitor MG132 (Fig. 2C).
MG132 is a peptide aldehyde that acts as a potent com-
petitive inhibitor of the chymotrypsin-like activity of the
proteasome complex [34]. To validate further the possi-
bility that cadmium down-regulates the expression of
XIAP at the post-transcriptional level via proteasome-
mediated NF-B-independent mechanism, we trans-
fected PC-3 cells with the N-terminally HA-tagged
XIAP constructs under the control of the NF-B-inde-
pendent SV40 promoter [35]. As demonstrated in Figure
2A and 2D, cadmium completely blocked XIAP expres-
sion irrespective of the transcriptional origin. This was
documented by Western blotting analysis using the anti-
HA antibody. In addition, pre-treatment with a proteasome
Figure 1 Effect of cadmium on XIAP protein and mRNA levels in prostate cancer cells. (A) PC-3 and DU-145 cells were treated with
indicated concentrations of cadmium for 16 hours. Levels of XIAP, cIAP1 and c IAP2 proteins were detected in cell lysates by immunoblotting
using specific antibodies. Expression of b-actin was used to control equal protein loading. Representative data from one of four experiments is
shown. (B) The effect of cadmium on the viability of PC-3 and DU-145 cells. Cells were cultured in the absence or presence of cadmium (30 μM)
for 16 hours, harvested and stained with propidium iodide followed by flow cytometry analysis. X axis represents fluorescence intensity, Y axis
represents cell number. Representative data from one of three experiments. (C) PC-3 and DU-145 cells were treated with cadmium (30 μM) for
indicated periods of time. XIAP mRNA levels were examined by real-time PCR analysis as described in Materials and Methods.
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XIAP, whereas treatment with NF-B inhibitor, BAY 11-
7085, had no effect on the XIAP expression. Therefore, the
results of our experiments reveal that cadmium down-
regulates expression of XIAP through an NF-B-indepen-
dent, proteasome-mediated mechanism.
The potential sensitivity of various domains of XIAP
to cadmium-mediated down-regulation was also exam-
ined in PC-3 cells. These cells were transfected with the
appropriately truncated constructs containing N-term-
inal HA-tag under the control of SV40 promoter. As
shown in Figure 3A, the expression of all examined
XIAP domains was reduced in the presence of cadmium,
as was the expression of the full length XIAP protein.
Similar results were obtained with XIAP constructs car-
rying mutations of the zinc binding sites. As
demonstrated in Figure 3B, mutations of zinc binding
sites didn’t protect XIAP from cadmium-mediated
depletion.
Given that other D-block transition metals such as
copper can also modulate XIAP expression at the post-
transcriptional level [36], cell culture medium was sup-
plemented with various metal ions. As demonstrated in
Figure 4A, the addition of cadmium, but not other
metals was responsible for reduction of XIAP expres-
sion. Cadmium belongs to the same chemical group as
the metal zinc and competes with this element for
cysteinyl clusters in many proteins [26,37]. Therefore,
we examined whether the supplementation with zinc
could restore XIAP expression in the presence of cad-
mium. The results presented in Figure 4B demonstrate
that the addition of zinc failed to restore XIAP
Figure 2 Modulation of XIAP expression by cadmium occurs via NF-kappaB–independent, proteasome-mediated mechanism. (A) The
effect of NF-B inhibitor BAY 11-7085 and proteasome inhibitor MG132 on the expression of XIAP, cIAP1 and cIAP2 in PC-3 prostate cancer cells.
Cells were treated with either BAY 11-7085 (5 μM) or MG132 (5 μM) for 16 hours. Levels of XIAP, cIAP1 and c IAP2 proteins were detected in cell
lysates by immunoblotting using specific antibodies. Expression of a-actin was used to control equal protein loading. (B) Luciferase reporter
assay of NF-B activity in PC-3 cells. Cells were pre-incubated with cadmium (30 μM) or NF-B inhibitor BAY 11-7085 (5 μM) for 3 hours followed
by incubation with or w/o TNF-a (20 ng/ml) for an additional 4 hours. Columns, means of three different samples; bars, SEM. (C) Analysis of
proteasome activity in PC-3 cells. Cells were incubated with cadmium (30 μM) or the proteasome inhibitor MG132 (5 μM) for 3 hours.
Chymotrypsin- and trypsin-like activities were examined as described in Materials and Methods. Columns, means of three different samples; bars,
SEM. (D) PC-3 cells were transfected with the N-terminally HA-tagged XIAP construct under the control of the NF-B independent SV40
promoter. Four hours after transfection cell culture medium was replaced with medium containing either cadmium (30 μM) or MG132 (5 μM) or
BAY 11-7085 (5 μM) and cells were cultured for additional 16 hours. Expression of XIAP and a-actin was detected by immunoblotting with anti-
HA or anti-actin antibodies respectively. Representative data from one of three experiments is shown.
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determine whether down-regulation of XIAP expression
is a reversible process, we replaced cadmium-containing
medium with fresh medium without cadmium. Deple-
tion of cadmium from the cell culture medium comple-
tely restored XIAP expression in PC-3 cells after
4 hours (Fig. 4B).
Cadmium sensitizes prostate cancer cells to TNF-a-
mediated apoptosis
The inhibition or down-regulation of XIAP lowers the
apoptotic threshold [17,38,39]. Therefore, we evaluated
the pro-apoptotic effect of cadmium in combination
with TNF-a on prostate cancer cells. Treatment with
TNF-a alone had no significant effect on cell death in
PC-3 cells, as prostate cancer cells are generally resistant
to TNF-a-mediated apoptosis. Treatment with cadmium
alone induced apoptosis only in 16% of cells as was
detected by the TUNEL assay. Concomitant treatment
with TNF-a and cadmium, on the other hand, induced
apoptosis in 53% of cells (Fig. 5A). We demonstrated
previously that direct small interfering RNA-mediated
knockdown of XIAP results in sensitization of PC-3
cells to death ligand-mediated apoptosis, suggesting that
depletion of XIAP by itself is sufficient to reverse apop-
tosis resistance in prostate cancer cells [40]. Recent stu-
dies reveal that caspase family members induce XIAP
cleavage under stress conditions [41]. The inhibition of
caspase activity with the pan-caspase inhibitor Z-VAD-
FMK efficiently blocked apoptosis in PC-3 cells conco-
mitantly treated with TNF-a and cadmium (Fig. 5A).
However, Z-VAD-FMK did not block the ability of cad-
mium to reduce the XIAP protein levels (Fig. 5B), indi-
cating that cadmium-mediated down-regulation of XIAP
protein levels is a caspase-independent process.
Acquisition of apoptosis-resistance can potentially
contribute to progression of prostatic malignancies. We
investigated whether prolonged treatment with cadmium
results in selection of prostate cancer cells with cad-
mium-resistant phenotype. PC-3 cells were pre-treated
with cadmium at 30 μM for 7 days. As demonstrated in
Figure 5C, expression of XIAP in cadmium-selected PC-
3 cells (PC-3-Cd) was not modified after treatment with
escalating concentrations of cadmium, whereas cad-
mium completely reduced XIAP protein levels in paren-
tal PC-3 cells at all tested concentrations. Moreover,
cadmium-selected PC-3 cells were also resistant to
apoptosis in response to concomitant treatment with
TNF-a and cadmium (Fig. 5D). Our experiments
demonstrate that indeed cadmium treatment results in
the establishment of cadmium resistant phenotype in
prostate cancer cells.
Discussion
Cadmium is a toxic heavy metal. Its wide use in industry
is suspected to have widespread deleterious effects on
human health through occupational and environmental
exposure. The element contributes to pathogenesis of
osteoporosis, non-hypertrophic emphysema, irreversible
renal tubular injury, anemia, eosinophilia, anosmia and
chronic rhinitis. In addition, cadmium is a potent
human carcinogen and occupational exposure to the
metal is associated with cancers of the lung, prostate,
pancreas, and kidney [42]. The biological half-life of
cadmium in humans is estimated to be >25 years,
thereby assuring the metal’s accumulation in tissues
during one’s lifetime [3]. Therefore, cadmium
Figure 3 Cadmium blocks expression of various XIAP domains.
(A) PC-3 cells were transfected with the indicated HA-tagged XIAP
constructs or (B) BIR 1-2 constructs with point mutations in zinc
binding sites under the control of the SV40 promoter. Four hours
after transfection cell culture medium was replaced with medium
containing cadmium (30 μM) and cells were cultures for an
additional 16 hours. Expression of XIAP truncated mutants and a-
actin was detected by immunoblotting with anti-HA or anti-actin
antibodies, respectively. Representative data from one of three
experiments.
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increasing age. Indeed, the prostate is an organ with one
of the highest levels of cadmium [4,5].
Multiple mechanisms of carcinogenesis for cadmium
have been suggested. These include aberrant gene
expression, inhibition of DNA damage repair, induction
of oxidative stress, and inhibition of apoptosis [43]. In
contrast, some studies demonstrate that cadmium can
inhibit the formation of chemically induced and sponta-
neously occurring tumors in animals when given at
non-toxic concentrations [44,45].
The present study provides the first evidence that cad-
mium induces depletion of XIAP in prostate caner cells
at the post-transcriptional level via proteasome-mediated
mechanisms. The inhibition or down-regulation of XIAP
in cancer cells lowers the apoptotic threshold, thereby
inducing cell death and/or enhancing the cytotoxic
action of chemotherapeutic agents. Recent studies
demonstrate that XIAP antagonist 1396-34 sensitizes
PC-3 and DU-145 prostate cancer cells to chemothera-
peutic agents and TRAIL [46]. In accord with these
reports, our data show that cadmium-mediated down-
regulation of XIAP coincides with increased sensitivity
of PC-3 prostate cancer cells to TNF-a-mediated
apoptosis.
Cadmium induces generation of reactive oxygen spe-
cies in target cells with subsequent mitochondrial
damage [47]. Mitochondrial collapse results in the
release of various apoptogenic factors into the cyto-
plasm. These include IAP-binding proteins Smac/DIA-
BLO and Omi/HtrA2 [48]. Interestingly, both Smac/
DIABLO and Omi/HtrA2 are capable of inducing cas-
pase-independent degradation of IAPs including XIAP,
cIAP1 and cIAP2 [49-51]. However, the potential invol-
vement of Smac/DIABLO and Omi/HtrA2 in cadmium-
mediated XIAP depletion could be excluded based on
the findings that Smac/DIABLO selectively reduces the
protein levels of cIAP1 and cIAP2 but not that of XIAP
[51], whereas Omi/HtrA2 induces proteolytic cleavage
of all IAPs (i.e. XIAP, cIAP1 and cIAP2) [50]. Impor-
tantly, cadmium-mediated depletion of XIAP was selec-
tive, as cadmium had no effect on the levels of other
members of the IAP family, namely cIAP1 and cIAP2
(Fig. 1A).
Selection of apoptosis-resistant cells is a potential
mechanism for tumor progression. Results of our
experiments reveal that pre-treatment with cadmium
produces development of apoptosis-resistance in
response to concomitant treatment with TNF-a and
cadmium in prostate cancer cells (Fig. 5D). Develop-
ment of apoptosis-resistance coincides with restoration
of XIAP expression in cadmium-selected PC-3 cells.
Interestingly, while some studies demonstrate that high
levels of XIAP have an unfavorable prognosis in can-
cers of various tissue origins [21,52], other data suggest
that elevated XIAP levels are associated with a favor-
able clinical outcome [53,54]. Likely, XIAP expression
alone cannot serve as a predictive marker of chemore-
sistance. Given that tumorigenesis is a complex multi-
factorial process, expression levels and functional
states of other critical pro- and anti-apoptotic mole-
cules must be integrated for accurate prognostication.
Recent studies by Seeger et al. demonstrate that the
finely tuned balance between XIAP and its antagonists
is critical in determining the clinical outcome in can-
cer patients [55].
Figure 4 The effect of metal ions on XIAP expression. (A) Expression of XIAP in prostate cancer cells was prevented by cadmium only but
not by other tested metal ions. PC-3 cells were transfected with the HA-tagged XIAP construct under the control of the SV40 promoter. Four
hours after transfection cell culture medium was replaced with medium containing 30 μM of indicated metal salts and cells were cultured for
additional 16 hours. Expression of XIAP and a-actin was detected by immunoblotting with anti-HA or anti-actin antibodies respectively. (B) PC-3
cells were transfected with the HA-tagged XIAP construct under the control of the SV40 promoter. Four hours after transfection cell culture
medium was replaced with medium containing cadmium (30 μM) and cells were cultured for an additional 16 hours with or without equimolar
concentration of zinc. In an additional set of experiments, cells were first incubated in cadmium-containing medium. After 16 hours, all medium
containing cadmium was removed and replaced with fresh medium. Cells were then incubated for an additional 4 hours in the absence of
cadmium.
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mium-resistant phenotype in prostate cancer cells is
increased expression of metallothioneins in response to
cadmium treatment, resulting in the intracellular chela-
tion of cadmium ions. Albrecht et al. demonstrated that
exposure of the normal prostate cells to cadmium
results in the rapid induction of the various metallothio-
nein isoforms with eventual accumulation easily exceed-
ing 10% of total cellular protein. Moreover, maximum
accumulation of metallothioneins was detected on days
7-13 after the start of treatment [56].
Recent reports suggest that several metals may modu-
late XIAP integrity. For instance, elevated copper levels
result in a conformational change in XIAP, which
accelerates its degradation. Importantly, copper does not
reduce XIAP mRNA expression [36]. These data indi-
cate that both cadmium and copper modulate XIAP
expression at the post-transcriptional level. Despite
these published reports in cell culture of other tissues,
our experiments suggest that copper’se f f e c t so nX I A P
expression in prostate tissues are not as significant,
since pre-treatment with copper had no effect on XIAP
expression in prostate cancer cells (Fig. 4A).
Given cadmium’s chemical similarity to zinc, a possi-
bility exists that cadmium exchanges for zinc and leads
to instability of the XIAP protein. The selective antagon-
ism by zinc of the carcinogenic effect of cadmium sug-
gests that zinc may act at a variety of important binding
Figure 5 Cadmium sensitizes prostate cancer cells to TNF-alpha-mediated apoptosis. (A) PC-3 cells were pre-treated with cadmium (30
μM) for 16 hours followed by stimulation with TNF-a (20 ng/ml) with or without Z-VAD.FMK (50 μM) for an additional 20 hours. The percentage
of apoptotic cells was determined by the APO-BRDU assay followed by flow cytometry analysis. Representative data from one of three
experiments is shown. (B) PC-3 cells were pre-incubated with or without Z-VAD.FMK (50 μM) for 30 minutes followed by treatment with
cadmium (30 μM) for 16 hours. XIAP expression was detected in cell lysates by immunoblotting with specific antibody. (C) PC-3 cells were
cultured in medium alone or in the presence of cadmium (30 μM) for 7 days followed by treatment with indicated concentrations of cadmium
for 16 hours. XIAP expression was detected in cell lysates by immunoblotting. (D) Aliquots of cells described in panel C were pre-treated with
cadmium (30 μM) for 16 hours followed by stimulation with TNF-a (20 ng/ml) for an additional 20 hours. The percentage of apoptotic cells was
determined by the APO-BRDU assay. Representative data from one of three experiments is shown.
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regulation of gene expression or of the enzyme’s cataly-
tic activity. Indeed, the ability of cadmium, to substitute
zinc in the zinc finger domains and impair function of
the wild-type zinc finger proteins has been demon-
strated [26]. Cadmium’s substitution for zinc in the
tumor suppressor protein, p53 alters p53 conformation
and results in loss of DNA binding capacity and sup-
pression of p53-dependent cell cycle arrest. Zinc supple-
mentation, on the other hand, reactivates p53 and
restores its tumor suppressive functions [26]. Indeed,
zinc and cadmium are the only two metal ions that
appear to effect cellular XIAP levels. In contrast to cad-
mium, it is the depletion of zinc that leads to cellular
reduction of XIAP [40]. Nevertheless, in contrast to data
available for p53, zinc supplementation in our hands
failed to restore expression of XIAP in cells treated with
cadmium (Fig. 4B).
XIAP is one of the NF-B-regulated proteins [28].
Nevertheless, our data suggest that suppression of XIAP
expression by cadmium is likely an NF-B-independent
process. Our work shows that cadmium reduces XIAP
levels even when the protein is expressed under an NF-
B-independent SV40 promoter. Instead, the mechan-
ism for XIAP suppression may be proteasome-
dependent.
Conclusions
In this study we investigated the molecular mechanisms
of cadmium-mediated XIAP down-regulation in prostate
cancer cells. Our results demonstrate that cadmium
down-regulates the expression of XIAP at post-tran-
scriptional level via an NF-B-independent mechanism.
Furthermore, our work reveals the critical role of a pro-
teasome-dependent mechanism for the cadmium-
mediated modulation of XIAP expression.
Methods
Cells and materials
Cell lines were obtained from ATCC (Rockville, MD)
and maintained in RPMI 1640 medium (Bio-Whittaker,
Walkersville, MD) supplemented with 10% FBS
(Hyclone, Logan, UT), gentamicin (50 mg/L), sodium
pyruvate (1 mM) and non-essential amino acids (0.1
mM).
Antibodies and Reagents
Antibody to HA-tag was obtained from Santa Cruz Bio-
t e c h n o l o g y( S a n t aC r u z ,C A ) .A n t i b o d yt oX I A Pw a s
obtained from Cell Signaling Technology (Beverly, MA).
TNF-a and antibody to b-actin were obtained from
Sigma (St. Louis, MO). MG132, BAY 11-7085 and Z-
VAD.FMK were obtained from Biomol (Plymouth Meet-
ing, PA).
Western Blot Analysis
Cells were lysed in a boiling SDS buffer (66 mM Tris-
HCl (pH 7.5), 2% SDS) for 10 minutes. SDS-PAGE and
Western blotting were performed as previously
described [57].
Real-Time PCR analysis
Total RNA was isolated from cells using Mini RNA iso-
lation II Kit (Zymo Research, Orange, CA) following
with DNase I (New England Biolabs, Ipswich, MA)
treatment. RNA was purified using RNA Clean and
Concentrator Kit (Zymo Research). Total RNA (1 μg)
was reverse transcribed in final volume of 20 μlw i t h
100 U of Superscript III Reverse Transcriptase (Invitro-
gen, Gaithersburg, MD) according to the manufacturer’s
instructions. After reverse transcription cDNA samples
were diluted 40 fold, and 5 μl of diluted cDNA were
amplified by real-time PCR using the XIAP TaqMan
Gene Expression Assay (ID# Hs00745222_s1). GAPDH
Gene Expression Assay (ID# Hs99999905_m1) was used
as endogenous control. Each sample was run in tripli-
cate for both XIAP and GAPDH in 20 μl reaction using
TaqMan Gene Expression Master Mix according to the
manufacturer’s instructions (Applied Biosystems, Foster
City, CA). Reactions were carried out in an Applied Bio-
systems 7500 real-time PCR System. Analysis of relative
XIAP gene expression data was carried out using the
2
-ΔΔCT method [58].
Plasmids and transfection
pEBB-HA-XIAP vector and XIAP truncation mutants
w e r eak i n dg i f tf r o mD r .C .S .D u c k e t t( U n i v e r s i t yo f
Michigan Medical School, Ann Arbor, MI). Transfec-
tions were performed using TransIT-Prostate transfec-
tion kit (Mirus Bio, Madison, WI).
Luciferase reporter assay
Cells were transfected with pNF-B-luc (Stratagene, La
Jolla, CA) and pRL-TK (Promega, Madison, WI) plas-
mids. Twenty-four hours after transfection, cells were
treated with cadmium (30 μM) or NF-B inhibitor BAY
11-7085 (10 μM) for 3 hours followed by treatment with
TNF-a (20 ng/ml) for an additional 4 hours. Samples
were assayed for firefly and renilla luciferase activities
using the Dual-Glo Luciferase assay System (Promega)
and normalized as instructed by the manufacturer.
Zinc finger mutagenesis
The strategies for nonfunctional zinc finger mutation
have been described previously [59]. C63V and C66S
mutations of zinc finger in BIR1 domain of XIAP BIR1-
2 polypeptide were generated by PCR with overlapping
internal primers spanning the mutated region and exter-
nal primers containing restriction sites (underlined in
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BIR1-2 ORF was used as a template. Briefly, two PCR
products were amplified using first forward 5′-atcttgg-
gatccATGACTTTTAACAGTTTTGAAGG and reverse
5′-TGtgaACTAAAgacCCGCACGGT primer pairs and
second forward 5′-ACCGTGCGGgtcTTTAGTtcaCA
and reverse 5′-atcttgatcgat TTAGGATGGATTTCTTG-
GAAGATTTG primer pairs. These PCR products were
purified, diluted, mixed and re-amplified with external
primers for subsequent cloning into pEBB vector. The
same strategy was used to generate H220A and H223A
mutations in the BIR2 domain of XIAP BIR1-2 polypep-
tide. Overlapping internal primers had 5′-GAAgc-
cAGGCGAgccTTTCCTAATT and 5′-AATTAGGTTT
ggcTCGCCTggcTTC sequences, while external primers
remained the same. All mutations were confirmed by
sequencing in the Fox Chase Cancer Center Automated
DNA Sequencing Facility.
Measurement of apoptosis
DNA fragmentation was detected using APO-BRDU kit
(The Phoenix Flow Systems, Inc., San Diego, CA).
Measurement of proteasome activity
Cells were lysed in a buffer (50 mM Tris (pH 7.6), 150
mM NaCl, 1% Triton X-100). Protein concentration was
measured with a commercial kit (Bio-Rad, Richmond,
CA). The proteasome activity assay was performed in
96-well plates by incubating 10 μgo fp r o t e i n sw i t h
fluorescent proteasome substrates (Biomol, Plymouth
Meeting, PA) as suggested by the manufacturer.
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